The targeted dose for this study was 10 Gy 14 days post-injection using the prostate tumor model29, and the dose delivered to PC cells was better conformed to the target dose in [177Lu]Lu- compared to [225Ac]Ac-PSMA-targeted RPT (Table S1, Figure S2C). The gene discussed is FOLH1; the disease is prostate neoplasm.